29.10.2012 • News • Nomad Bioscience • Bayer • Agrochemistry

Nomad Bioscience, Bayer Cropscience to Enter into Strategic Partnership

Nomad Bioscience, a plant biotechnology company, has announced that the company has entered into a strategic joint research and development agreement with Bayer CropScience, Monheim, Germany.

The multi-year collaboration continues an earlier research program and provides Bayer CropScience broad exclusivity with regard to crop species and plant traits. The financial and other material provisions of the agreement were not disclosed.

Dr. Yuri Gleba, Nomad's CEO said: "Since the advent of genetically engineered plants that have been first produced in 1982 and commercialized in 1994, this is the only new technology with huge business potential, one that allows to extract value in agriculture in an entirely different way. To bring it to the market is a massive undertaking, and we are extremely happy to have one of the largest agribusiness companies as our strategic partner.

 

 

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Top-Feature

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.